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Background. Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-
negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections 
are limited. The pivotal phase III REPROVE trial evaluated the efficacy of ceftazidime-avibactam (CAZ-AVI) vs meropenem in the 
treatment of patients with HAP/VAP. Study results for prespecified analyses per US Food and Drug Administration–recommended 
trial end points are reported here.
Methods. Hospitalized adults with HAP/VAP proven or suspected to be caused by a Gram-negative pathogen were randomized 
1:1 to receive CAZ-AVI or meropenem for 7 to 14 days. The primary outcome was 28-day all-cause mortality in the intent-to-treat 
(ITT) population. Secondary outcomes included clinical cure at test of cure (TOC) in the ITT and microbiological ITT (micro-ITT) 
populations, and safety and tolerability throughout the study.
Results. Eight hundred seventy randomized patients received treatment and were included in the ITT population (CAZ-AVI, 
n = 436; meropenem, n = 434). CAZ-AVI was noninferior to meropenem for the primary end point (28-day all-cause mortality; ITT) 
based on the prespecified 10% noninferiority margin (CAZ-AVI, 9.6%; meropenem, 8.3%; difference, 1.5%; 95% confidence interval 
[CI], –2.4% to 5.3%) and for the clinical cure end point in the ITT population based on a prespecified –10% noninferiority margin 
(CAZ-AVI, 67.2%; meropenem, 69.1%; difference, −1.9%; 95% CI, –8.1% to 4.3%). Clinical cure rates at TOC for patients infected 
with CAZ-nonsusceptible pathogens were similar (CAZ-AVI, 75.5%; meropenem, 71.2%; micro-ITT). Safety data were consistent 
with established safety profiles for both agents.
Conclusions. CAZ-AVI provides an important new treatment option for HAP/VAP due to Gram-negative pathogens, including 
CAZ-nonsusceptible strains.
Keywords.  ceftazidime-avibactam; hospital-acquired pneumonia; meropenem; nosocomial pneumonia; ventilator-associated 
pneumonia.
Hospital-acquired and ventilator-associated bacterial pneu-
monia (HAP/VAP; nosocomial pneumonia) are collectively the 
leading cause of death due to hospital-acquired infections world-
wide [1–4]. Gram-negative bacilli, including Enterobacteriaceae 
and Pseudomonas aeruginosa, are the most common etio-
logic HAP/VAP pathogens; treatment is complicated by the 
increasing prevalence of β-lactamase-producing, multidrug-
resistant (MDR) strains [5, 6].
Ceftazidime-avibactam (CAZ-AVI) combines a third-
generation cephalosporin with the non-β-lactam β-lactamase 
inhibitor avibactam, which exhibits broad-spectrum inhi-
bition of clinically relevant serine β-lactamases, including 
AmpC, extended-spectrum β-lactamases (ESBLs), Klebsiella 
pneumoniae carbapenemase (KPC), and OXA-48 enzymes 
[7–9]. CAZ–AVI has demonstrated activity against common 
Gram-negative HAP/VAP pathogens [10–12], including certain 
drug-resistant (ESBL- and KPC-producing) Enterobacteriaceae 
and MDR P. aeruginosa strains, which are classified as serious 
and/or urgent threats to US public health [13, 14].
The clinical efficacy of CAZ-AVI for the treatment of serious 
Gram-negative bacterial infections has been previously estab-
lished in phase III trials of complicated intra-abdominal and com-
plicated urinary tract infections, which each included subsets 
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of patients with infections due to ceftazidime-nonsusceptible 
(CAZ-NS) Gram-negative pathogens, supporting approval for 
both indications in the United States and Europe [10–12].
The global phase III REPROVE study (ClinicalTrials.gov, 
NCT01808092; EudraCT 2012-004006-96) evaluated the effi-
cacy and safety of CAZ–AVI vs meropenem in the treatment of 
hospitalized adults with HAP/VAP (nosocomial pneumonia) due 
to Gram-negative pathogens, including CAZ-NS strains. Primary 
efficacy end points and analysis populations for the study were 
separately defined for the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) to comply 
with the respective regulatory requirements. Study results 
presented here for analyses according to the FDA-specified trial 
end points supported the recent FDA approval of CAZ–AVI for 
the treatment of adults with HAP/VAP, representing the first 
Gram-negative antimicrobial approved in the United States for 
this indication in over 15  years [15]. Results of the study ac-
cording to the primary end points and analysis populations de-
fined for the EMA have been previously reported [16].
METHODS
Study Design
The REPROVE study design (Supplementary Figure 1) and con-
duct were previously described [16]. Additional details relevant 
to the summary of data for the US analyses are presented here. 
The study was conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines, and applicable 
regulatory requirements. The study protocol and amendments 
were approved by local ethics committees and/or institutional 
review boards.
Study Population
Patients were recruited in 24 countries. Eligible patients in-
cluded hospitalized adults (aged 18–90  years) with HAP, de-
fined as pneumonia with onset ≥48 hours after admission or 
within 7  days of discharge from an inpatient care facility, or 
VAP, defined as a parenchymal lung infection arising ≥48 hours 
after endotracheal intubation and mechanical ventilation. Key 
inclusion and exclusion criteria are provided in Supplementary 
Table 1.
Study Procedures
Patients were randomized 1:1 to receive either CAZ-AVI 2.5 g 
(2.0 g ceftazidime + 0.5 g avibactam) every 8 hours (q8h) in-
travenously (IV) over 2 hours (as approved for the treatment 
of complicated urinary tract and intra-abdominal infections) 
plus meropenem placebo, or meropenem 1  g q8h IV over 30 
minutes plus CAZ-AVI placebo for 7 to 14  days. Treatment 
doses for both drugs were adjusted in patients with moderate to 
severe renal impairment at baseline (MSRIB; creatinine clear-
ance [CrCl] 16–50 mL/min) (Supplementary Table 2). A pro-
tocol amendment in year 3 (of 4)  of the study increased the 
CAZ-AVI dose for patients with MSRIB by 50% (MSRIBnew), 
consistent with the approved dose recommendations [7] based 
on emerging data from the phase III CAZ-AVI program [11]. 
From randomization, patients could receive empiric open-label 
linezolid or vancomycin to cover for Gram-positive pathogens 
and/or empiric open-label amikacin or other aminoglycoside 
for possible MDR Gram-negative organisms for up to 72 hours, 
pending pathogen identification and susceptibility results, after 
which open-label therapy was de-escalated as appropriate.
Outcome Measures
The primary end point for the US analysis was 28-day all-cause 
mortality (death from any cause by the day 28 visit [28–32 days 
from randomization]) in the intent-to-treat (ITT) population. 
Key secondary end points were clinical cure at test of cure 
(TOC; 21–25  days from randomization) in the ITT popula-
tion and 28-day all-cause mortality in the microbiological ITT 
(micro-ITT) population. Additional secondary outcomes in-
cluded clinical and microbiological responses in the micro-ITT 
population (including patients infected with CAZ-NS Gram-
negative pathogens) and safety/tolerability throughout the study 
(Supplementary Table 3). Clinical and microbiological response 
definitions and definitions of the US analysis populations are 
provided in Supplementary Tables 4 and 5, respectively.
Statistical Analysis
Noninferiority for the US primary end point was to be 
concluded if the upper limit of the 2-sided 95% confidence in-
terval (CI) for the difference in 28-day all-cause mortality rate 
between treatments (CAZ-AVI minus meropenem) was <10%. 
The sample size ensured ≥90% power for a 10% noninferiority 
margin. Sensitivity and subgroup analyses for the primary end 
point were also performed. Noninferiority for the key sec-
ondary end point, clinical cure at TOC (ITT population), was 
to be concluded if the lower limit of the 2-sided 95% CI for the 
difference between treatments was above –10%. Details on sta-
tistical methodology are provided in the Supplementary Data.
RESULTS
Patient Characteristics
Between April 2013 and January 2016, 879 patients were 
randomized; 870 received treatment and were included in the 
ITT population (CAZ-AVI, n  =  436; meropenem, n  =  434) 
(Figure 1). Median exposure to IV study drug in both treatment 
arms was 10  days. Patient demographics and disease charac-
teristics were well balanced between treatment arms (Table 1) 
and were as expected for patients with HAP/VAP. Most patients 
(73.8%) had normal renal function or mild renal impairment 
(CrCl >50 and ≤150 mL/min) at baseline, and 14.0% had poten-
tially augmented renal clearance (CrCl >150 mL/min). Among 
102 (11.7%) patients in the ITT population with MSRIB (CrCl 
16–50  mL/min), 62 (31 in each treatment arm) were enrolled 
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before the protocol amendment for the increase in CAZ-AVI dose 
(MSRIBorig), and 40 (CAZ-AVI, n = 21; meropenem, n = 19) were 
enrolled after the protocol amendment (MSRIBnew). As allowed 
per protocol, 81% of patients in both treatment arms received 
concomitant aminoglycoside antibiotics at any point up to end 
of treatment (EOT); for most patients, exposure was ≤72 hours.
The micro-ITT population comprised 382 patients (CAZ-
AVI, n  =  187; meropenem, n  =  195) for whom ≥1 Gram-
negative pathogen was isolated from baseline respiratory and/or 
blood culture, including 164 (43%) patients with polymicrobial 
infections, of whom 73 (19%) had both Gram-positive and 
Gram-negative aerobic pathogens isolated.
As expected, most infections were due to Enterobacteriaceae 
(CAZ-AVI, 133/187 [71.1%]; meropenem, 147/195 [75.4%]) 
(Supplementary Table 6). The distribution of baseline pathogens 
was similar between treatment arms, with the exception of 
P. aeruginosa, which was more prevalent in the CAZ-AVI arm. 
Among patients in the micro-ITT population, 108 (28.3%) 
were infected with ≥1 Gram-negative pathogen that was 
nonsusceptible to ceftazidime based on Clinical and Laboratory 
Standards Institute (CLSI)–defined criteria [17] for ceftazidime-
resistant and -intermediate susceptibility categories (ie, 
minimum inhibitory concentration [MIC] ≥8  mg/L for 
Enterobacteriaceae and ≥16 mg/L for P. aeruginosa), including 
53 patients with K. pneumoniae and 28 with P. aeruginosa. In a 
subset of Gram-negative pathogens that met phenotypic (MIC) 
screening criteria for the presence of a β-lactamase, genotypic 
testing identified certain ESBL groups (eg, TEM-1, SHV-12, 
Assessed for eligibility (n = 969)
Randomized (n = 879)
Assigned to CAZ-AVI arm (n = 440) Assigned to meropenem arm (n = 439)
Received meropenem (n = 434)Received CAZ-AVI (n = 436)
Completed study (n = 383) Completed study (n = 388)
Did not receive treatment (n = 4)
• Patient decision (n = 1)
• Death (n = 2)
• Other (n = 1)
436 in ITT population
187 in micro-ITT population
291 in CE population at EOT
257 in CE population at TOC
143 in extended ME population at EOT
125 in extended ME population at TOC
122 in ME population at EOT
107 in ME population at TOC
434 in ITT population
195 in micro-ITT population
306 in CE population at EOT
270 in CE population at TOC
151 in extended ME population at EOT
131 in extended ME population at TOC
138 in ME population at EOT
118 in ME population at TOC
Discontinued study (n = 45)
• Patient decision (n = 4)
• Death (n = 33)
• Lost to follow-up (n = 7)
• Other (n = 1)
Discontinued study (n = 53)
• Patient decision (n = 8)
• Death (n = 40)
• Lost to follow-up (n = 3)
• Other (n = 2)
Did not receive treatment (n = 5)
• Did not meet eligibility criteria (n = 1)
• Death (n = 1)
• Other (n = 3)
Excluded (n = 90)
• Not meeting inclusion criteria (n = 90)
Figure 1. Patient disposition. One patient in the meropenem arm completed the TOC visit (out of window) and the final protocol follow-up visit on the same day and was 
treated as having neither completed nor discontinued the study. Abbreviations: CAZ-AVI, ceftazidime-avibactam; CE, clinically evaluable; EOT, end of treatment; ITT, intent to 
treat; ME, microbiologically evaluable; micro-ITT, microbiological ITT; TOC, test of cure.
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Table 1. Patient Demographic and Baseline Clinical Characteristics (ITT Population)
Characteristic CAZ-AVI (n = 436) Meropenem (n = 434) Total (n = 870)
Age, mean (SD), y 62.8 (16.7) 62.8 (17.6) 62.8 (17.2)
 <65 y, n (%) 200 (45.9) 201 (46.3) 401 (46.1)
 ≥75 y, n (%) 129 (29.6) 135 (31.1) 264 (30.3)
Male, n (%) 325 (74.5) 320 (73.7) 645 (74.1)
Region, n (%)    
 Western Europe 37 (8.5) 34 (7.8) 71 (8.2)
 Eastern Europe 113 (25.9) 109 (25.1) 222 (25.5)
 China 143 (32.8) 145 (33.4) 288 (33.1)
 Rest of world 143 (32.8) 146 (33.6) 289 (33.2)
Race, n (%)    
 White 181 (41.5) 189 (43.5) 370 (42.5)
 Asian 245 (56.2) 236 (54.4) 481 (55.3)
 Other 10 (2.3) 9 (2.1) 19 (2.2)
BMI, mean (SD), kg/m2 23.8 (6.0) 23.6 (5.2) 23.7 (5.6)
APACHE II score, mean (SD) 14.6 (4.1) 15.0 (4.1) 14.8 (4.1)
APACHE II category, n (%)    
 <10 3 (0.7) 2 (0.5) 5 (0.6)
 10–19 376 (86.2) 369 (85.0) 745 (85.6)
 20–30 57 (13.1) 62 (14.3) 119 (13.7)
Renal function category,a n (%)    
 Normal renal function/mild renal impairment (CrCl >50–150 mL/min) 324 (74.3) 318 (73.3) 642 (73.8)
 Moderate or severe renal impairment (CrCl 16–50 mL/min) 52 (11.9) 50 (11.5) 102 (11.7)
 MSRIBorig 31 (7.1) 31 (7.1) 62 (7.1)
 MSRIBnew 21 (4.8) 19 (4.4) 40 (4.6)
 Augmented (CrCl >150 mL/min) 58 (13.3) 64 (14.7) 122 (14.0)
HAP/VAP subtype, n (%)    
 HAP 291 (66.7) 289 (66.6) 580 (66.7)
 VAP 145 (33.3) 145 (33.4) 290 (33.3)
Type of infection (VAP patients), n (%)    
 Early VAP 36 (8.3) 54 (12.4) 90 (10.3)
 Late VAP 109 (25.0) 91 (21.0) 200 (23.0)
Mechanically ventilated at baseline, n (%) 193 (44.3) 186 (42.9) 379 (43.6)
 VAP 145 (33.3) 145 (33.4) 290 (33.3)
 Ventilated HAP 48 (11.0) 41 (9.4) 89 (10.2)
Bacteremic, n (%) 24 (5.5) 18 (4.1) 42 (4.8)
 Micro-ITT population 21/187 (11.2) 15/195 (7.7) 36/382 (9.4)
Infection type, n (%)    
 Monomicrobial infection 141 (32.3) 130 (30.0) 271 (31.1)
  Micro-ITT population 111/187 (59.4) 107/195 (54.9) 218/382 (57.1)
 Polymicrobial infection 76 (17.4) 89 (20.5) 165 (19.0)
  Micro-ITT population 76/187 (40.6) 88/195 (45.1) 164/382 (42.9)
 No study-qualifying pathogen identified 219 (50.2) 215 (49.5) 434 (49.9)
Prior systemic Gram-negative antibiotic exposure,b n (%)    
 0–24 h 322 (73.9) 323 (74.4) 645 (74.1)
 >24 h 114 (26.1) 111 (25.6) 225 (25.9)
Concomitant aminoglycoside use up to EOT,c n (%)    
 0–72 h 334 (76.6) 344 (79.3) 678 (77.9) 
 >72 h 102 (23.4) 90 (20.7) 192 (22.1)
Abbreviations: APACHE,  Acute Physiology and Chronic Health Evaluation; BMI,  body mass index; CAZ-AVI,  ceftazidime-avibactam; CrCl,  creatinine clearance; EOT,  end of treatment; 
HAP, hospital-acquired bacterial pneumonia; ITT, intent to treat; micro-ITT, microbiological ITT; MSRIB, moderate to severe renal impairment at baseline; MSRIBnew, MSRIB cohort enrolled 
after protocol amendment for increased CAZ-AVI dose; MSRIBorig, MSRIB cohort enrolled before protocol amendment for increased CAZ-AVI dose; VAP, ventilator-associated bacterial 
pneumonia.
aBased on estimated CrCl per the Cockcroft-Gault method and local laboratory data.
bIn the 72 hours before randomization.
cExploratory analysis based on blinded review of postbaseline data.
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CTX-M-15, and KPC-2 carbapenemase) and AmpC that were 
expected to be inhibited by avibactam in isolates from 115/382 
(30.1%) patients in the micro-ITT population.
The MICs required to inhibit ≥90% of isolates with CAZ-
AVI or ceftazidime for 339 Enterobacteriaceae isolates were 
0.5 and 64  µg/mL, respectively, and 8 and 64  µg/mL for 111 
P. aeruginosa isolates (micro-ITT population). Thus, the CAZ-
AVI MIC distributions for Enterobacteriaceae and P. aeruginosa 
isolates were left-shifted compared with those for ceftazidime 
alone (Supplementary Figure 2). Two K.  pneumoniae isolates 
and 9 P. aeruginosa isolates were nonsusceptible to CAZ-AVI, 
and 6 Enterobacteriaceae isolates and 34 P. aeruginosa isolates 
were nonsusceptible to meropenem based on CLSI criteria.
Efficacy Results
Twenty-Eight-Day All-Cause Mortality
CAZ-AVI was noninferior to meropenem with respect to the 
US primary end point (28-day all-cause mortality; ITT popula-
tion) based on a 10% noninferiority margin (CAZ-AVI, 42/436 
[9.6%]; meropenem, 36/434 [8.3%]; difference, 1.5% [Kaplan-
Meier estimate]; 95% CI, −2.4 to 5.3). Results for the micro-
ITT population were consistent with the primary analysis 
(Table 2). Likewise, mortality rates among the subset of patients 
with CAZ-NS pathogens were similar between treatment arms 
(CAZ-AVI, 8.2% [4/49]; meropenem, 8.5% [5/59]).
Sensitivity analyses of the US primary end point 
(Supplementary Data) using multiple imputation of missing 
data at the day 28 visit, or excluding data for patients who 
were lost to follow-up, were consistent with the primary anal-
ysis (Supplementary Table 7), as were subgroup analyses based 
on key patient characteristics for which mortality rates were 
broadly similar between the CAZ-AVI and meropenem arms 
(Figure 2). All CIs for the difference between treatment arms 
included 0.
Clinical Cure
CAZ-AVI was noninferior to meropenem with respect to the 
key secondary end point (clinical cure at TOC; ITT popula-
tion) based on a –10% noninferiority margin; clinical cure was 
achieved in 293 (67.2%) patients in the CAZ-AVI arm and 300 
(69.1%) patients in the meropenem arm (difference, –1.9; 95% 
CI, –8.1 to 4.3). In the micro-ITT population, including patients 
infected with CAZ-NS pathogens, 75.5% and 71.2% in the CAZ-
AVI and meropenem arms, respectively, achieved clinical cure 
at TOC (Figure 3). Clinical cure rates in both populations were 
slightly higher at EOT and were comparable between treatment 
arms. Favorable clinical response rates at TOC by baseline path-
ogen were generally similar between treatment arms across all 
baseline pathogens, although definitive comparisons are lim-
ited in these individual pathogen subsets (Table 3).
Microbiological Response
The overall per-patient favorable microbiological response 
(eradication or presumed eradication) rates at TOC were sim-
ilar between treatment arms in the micro-ITT and microbio-
logically evaluable populations, including patients infected 
with CAZ-NS pathogens (Figure 4). Per-pathogen favorable 
microbiological response rates at TOC in the micro-ITT popu-
lation were similar between treatment arms across all baseline 
pathogens, including CAZ-NS strains (Table 3). Overall eradi-
cation rates in the micro-ITT population for CAZ-NS Gram-
negative pathogens were 67.3% (35/52) in the CAZ-AVI arm 
and 51.6% (33/64) in the meropenem arm.
Among the subset of pathogens with an unfavorable micro-
biological response due to persistence of the baseline isolate, an 
increase in postbaseline MIC for study drug received (≥4-fold) 
was observed for 4/79 (5.1%) and 14/75 (18.7%) pathogens in 
the CAZ-AVI and meropenem arms, respectively, including 
2/65 (3.1%) and 3/75 (4.0%) K. pneumoniae isolates in the CAZ-
AVI and meropenem arms, respectively. Among P. aeruginosa 
isolates, however, 11/51 (21.6%) in the meropenem arm had 
an increase in postbaseline MIC, compared with 2/64 (3.1%) 
in the CAZ-AVI arm. The per-pathogen microbiological 
responses by MIC to study drug received were assessed for 
Enterobacteriaceae and P. aeruginosa. No trend in unfavorable 
microbiological outcomes was observed over the MIC range 
among Enterobacteriaceae isolates (CAZ-AVI MIC, 0.015 to 
4  µg/mL; meropenem MIC, 0.008 to >8  µg/mL), nor among 
clinical isolates of P. aeruginosa (CAZ-AVI MIC, 0.5 to >256 µg/
mL; meropenem MIC, 0.06 to >8 µg/mL), suggesting that ex-
posure to the study drug for both CAZ-AVI- and meropenem-
treated patients was adequate.
Table 2. Twenty-Eight-Day All-Cause Mortality (ITT and Micro-ITT Populations): Kaplan-Meier Estimates and Noninferiority Hypothesis Test
Analysis Population
Patient Deaths
Between-Arm
Differencea (95% CI), %CAZ-AVI, n/N (%) [KM%] Meropenem, n/N (%) [KM%]
ITT 42/436 (9.6) [9.9] 36/434 (8.3) [8.4] 1.5 (−2.4 to 5.3)
Micro-ITT 22/187 (11.8) 19/195 (9.7) 2.1 (–4.1 to 8.4)
 CAZ-NS 4/49 (8.2) 5/59 (8.5) −0.1
Abbreviations: CAZ-AVI, ceftazidime-avibactam; CAZ-NS, ceftazidime-nonsusceptible; CI, confidence interval; ITT, intent to treat; KM, Kaplan-Meier; micro-ITT, microbiological ITT.
aDifferences based on the KM estimates of the cumulative survival proportions for each treatment arm up to day 28; CIs for the difference were calculated based on Greenwood’s variance 
estimates.
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Safety
Overall, 74% of patients in both treatment arms experienced 
≥1 adverse event (AE) during the study. The majority of re-
ported AEs were of mild or moderate intensity and were bal-
anced between treatment arms (Table 4). The overall type and 
distribution of AEs were consistent with what is expected for 
patients with HAP/VAP and/or the known safety profile for 
both drugs. AEs resulted in discontinuation of study drug in 16 
(3.7%) patients in the CAZ-AVI arm and 13 (3.0%) patients in 
the meropenem arm.
Serious AEs (SAEs) were reported for 79 (18.1%) patients in 
the CAZ-AVI arm and 59 (13.6%) patients in the meropenem 
arm (Table 4). Consistent with the disease under study, the most 
common SAEs (reported in ≥1% of patients in either treatment 
arm) were pneumonia, respiratory failure, and sepsis. SAEs 
assessed by the investigator as possibly related to study drug 
were reported for 5 (1.1%) CAZ-AVI and 2 (0.5%) meropenem 
patients and were generally consistent with the established 
safety profile of the study drugs [16].
DISCUSSION
In the setting of a complex and evolving regulatory environ-
ment and the unique challenges to conducting randomized 
comparative studies in patients with HAP/VAP, there have 
been few registrational HAP/VAP trials conducted and no 
new antimicrobials approved for this indication by the FDA 
over the last decade [18–20]. Based on the positive results 
from the REPROVE study presented here, in 2018 the FDA 
approved CAZ-AVI for treatment of patients with HAP/
VAP. CAZ-AVI is thus the first new Gram-negative antibi-
otic approved in the United States for this indication in over 
15 years [18–21].
APACHE II category CAZ-AVI–meropenem
Renal status
Ventilated at baseline
Prior systemic antibiotic use
in the 72 hours before randomization:
Concomitant aminoglycoside therapy
10–19
20–30
MSRIB (CrCl ≥16 to ≤50 mL/min)
MSRIBorig
MSRIBnew
Normal renal function/mild renal
impairment (CrCl >50 to ≤150 mL/min)
Augmented renal function (CrCl >150 mL/min)  
(30/367) 8.2%–7.1% (26/364)
(12/55) 21.8%–16.4% (10/61)
(7/52) 13.5%–16.0% (8/50)
(33/313) 10.5%–8.0% (25/314)
(2/58) 3.4%–4.8% (3/62)
(23/191) 12.0%–12.0% (22/184)
(31/315) 9.8%–8.2% (26/319)
(11/110) 10.0%–9.2% (10/109)
(35/325) 10.8%–8.3% (28/339)
(7/100) 7.0%–9.0% (8/89)
Ventilated (VAP and ventilated HAP)
VAP
HAP
Ventilated HAP
Nonventilated HAP
0 to ≤24 hours
>24 hours
0 to ≤72 hours
>72 hours
–100 –50 0 50
Dierence in all-cause mortality (with 95% CI)
100
(19/234) 8.1%–5.7% (14/244)
(9/48) 18.8%–20.0% (8/40)
(28/282) 9.9%–7.7% (22/284)
(14/143) 9.8%–9.7% (14/144)
(3/21) 14.3%–10.5% (2/19)
(4/31) 12.9%–19.4% (6/31)
Figure 2. Subgroup analyses: 28-day all-cause mortality by patient baseline characteristics (ITT population). Based on difference between treatment arms in proportions 
of patients who died up to day 28; CIs for the difference were calculated using the unstratified Miettinen and Nurminen method. Abbreviations: APACHE, Acute Physiology 
and Chronic Health Evaluation; CAZ-AVI, ceftazidime-avibactam; CI, confidence interval; CrCl, creatinine clearance; HAP, hospital-acquired bacterial pneumonia; ITT, intent to 
treat; MSRIB, moderate to severe renal impairment at baseline; MSRIBnew, MSRIB cohort enrolled after protocol amendment for increased CAZ-AVI dose; MSRIBorig, MSRIB 
cohort enrolled before protocol amendment for increased CAZ-AVI dose; VAP, ventilator-associated bacterial pneumonia. 
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CAZ-AVI was noninferior to meropenem with respect to the 
FDA-specified primary end point of 28-day all-cause mortality 
in the ITT population and with respect to the key secondary 
end point of clinical cure at TOC in the ITT population. Results 
for the micro-ITT population and key patient subgroups were 
consistent with these analyses. Per-patient and per-pathogen 
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0
347
436
350
434
150
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300
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195
37
49
42
59
CAZ-AVI Meropenem
Figure 3. Clinical cure rates at EOT and TOC visits (ITT and micro-ITT populations). CIs for the difference between treatment arms were calculated using the unstratified 
Miettinen and Nurminen method. CI was not calculated for micro-ITT population because of small patient numbers. Abbreviations: CAZ-AVI,  ceftazidime-avibactam; 
CAZ-NS, ceftazidime-nonsusceptible; CI, confidence interval; EOT, end of treatment; ITT, intent to treat; micro-ITT, microbiological ITT; TOC, test of cure. 
Table 3. Favorable Clinical and Microbiological Response Rates at TOC by Baseline Pathogena (Micro-ITT Population)
Pathogen Group/Pathogen
Per-Patient Clinical Cureb Per-Pathogen Microbiological Eradicationc
CAZ-AVI, n/N (%) Meropenem, n/N (%) CAZ-AVI, n/N (%) Meropenem, n/N (%)
Aerobic Gram-negative 126/187 (67.4) 143/195 (73.3) 155/256 (60.5) 174/267 (65.2)
Enterobacteriaceae 92/133 (69.2) 108/147 (73.5) 111/168 (66.1) 126/182 (69.2)
 Enterobacter aerogenes 5/8 (62.5) 4/9 (44.4) 5/8 (62.5) 6/9 (66.7)
 Enterobacter cloacae 25/29 (86.2) 13/23 (56.5) 22/29 (75.9) 14/23 (60.9)
 Escherichia coli 12/22 (54.5) 17/23 (73.9) 14/22 (63.6) 16/23 (69.6)
 Klebsiella pneumoniae 44/65 (67.7) 56/75 (74.7) 39/65 (60.0) 54/75 (72.0)
 Proteus mirabilis 12/14 (85.7) 9/12 (75.0) 11/14 (78.6) 8/12 (66.7)
 Serratia marcescens 11/15 (73.3) 12/13 (92.3) 10/15 (66.7) 8/13 (61.5)
Gram-negative pathogens other than Enterobacteriaceae 54/85 (63.5) 61/84 (72.6) 44/88 (50.0) 48/85 (56.5)
 Haemophilus influenzae 13/16 (81.3) 20/25 (80.0) 14/16 (87.5) 23/25 (92.0)
 Pseudomonas aeruginosa 38/64 (59.4) 37/51 (72.5) 24/64 (37.5) 20/51 (39.2)
CAZ-NS pathogensd 37/49 (75.5) 42/59 (71.2) 35/52 (67.3) 33/64 (51.6)
 Enterobacteriaceae 29/36 (80.6) 31/45 (68.9) 31/40 (77.5) 29/47 (61.7)
 E. aerogenes 3/4 (75.0) 2/2 (100.0) 3/4 (75.0) 2/2 (100.0)
 E. cloacae 6/6 (100.0) 4/6 (66.7) 5/6 (83.3) 5/6 (83.3)
 E. coli 4/6 (66.7) 5/8 (62.5) 4/6 (66.7) 4/8 (50.0)
 K. pneumoniae 17/22 (77.3) 22/31 (71.0) 17/22 (77.3) 18/31 (58.1)
 P. aeruginosa 7/12 (58.3) 13/16 (81.3) 4/12 (33.3) 4/16 (25.0)
Abbreviations: CAZ-AVI, ceftazidime-avibactam; CAZ-NS, ceftazidime-nonsusceptible; CLSI, Clinical and Laboratory Standards Institute; micro-ITT, microbiological intent to treat; TOC, test 
of cure.
aRespiratory tract or blood source. Only pathogens with a combined total of ≥10 isolates across treatment arms (≥5 for CAZ-NS subset) are presented. Multiple isolates of the same species 
from the same patient are counted only once regardless of source (respiratory tract or blood) using the isolate with the highest minimum inhibitory concentration to study drug received.
bProportion of patients assessed as a clinical cure at TOC visit; percentages are based on the total number of patients in the subgroup (N).
cDefined as eradication or presumed eradication of the baseline pathogen at the TOC visit; percentages are based on the total number of unique pathogens (N).
dCAZ-NS designation was determined according to CLSI criteria for the ceftazidime-resistant and -intermediate categories [17].
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favorable clinical and microbiological response rates were gen-
erally high and similar between treatment arms across all visits 
and analysis populations, including the subset of patients with 
CAZ-NS pathogens, which represented 28% of the micro-ITT 
population. Among patients infected with P. aeruginosa, a sub-
stantially higher proportion in the meropenem arm had persist-
ence of the baseline pathogen associated with a ≥4-fold increase 
in postbaseline MIC to study drug received, raising concerns 
for potential treatment-emergent resistance. This is consistent 
with prior observations for imipenem-cilastatin in randomized 
controlled nosocomial pneumonia trials using other β-lactam 
or fluoroquinolone comparators, in which a higher incidence 
of treatment-emergent P.  aeruginosa resistance was reported 
among carbapenem-treated patients [22–24].
CAZ-AVI was well tolerated in patients with HAP/VAP; 
safety observations were consistent with the established safety 
profile for CAZ-AVI and/or ceftazidime [10–12, 25]. Although 
numerically higher among CAZ-AVI-treated patients, re-
ported SAEs were consistent with the underlying illness and/
or anticipated clinical course and do not appear to represent a 
safety signal for CAZ-AVI in this population.
Taken together, data from REPROVE indicate that CAZ-AVI 
is an effective therapy for patients with HAP/VAP due to Gram-
negative bacteria, including CAZ-NS strains. Study results 
demonstrating noninferiority vs a carbapenem comparator 
were robust across multiple sensitivity and subgroup analyses 
for the US primary end point and are consistent with previously 
reported analyses demonstrating noninferiority according to 
EMA-specified end points for HAP/VAP trials, reinforcing the 
robust nature of the data [16].
Of note, the study provides the first phase III assessment 
of the currently labeled CAZ-AVI dose regimens for patients 
with CrCl of 16–50 mL/min [7]. The original protocol-defined 
CAZ-AVI renal dosage adjustments (MSRIBorig) in REPROVE 
were consistent with those utilized in the earlier phase III CAZ-
AVI studies [10–12] but were modified during the trial based 
on emerging data from the phase III cIAI study (RECLAIM), 
which indicated a potential for underdosing in MSRIB patients 
with rapidly improving renal function early in the course of 
treatment [11]. Based on updated population pharmacokinetic 
analyses and pharmacokinetic/pharmacodynamic target at-
tainment simulations, the dosage regimens were changed for 
patients with MSRIB such that the total daily CAZ-AVI dose 
was increased by 50% (MSRIBnew) in order to ensure that CAZ-
AVI exposure in patients with fluctuating renal function would 
be maintained within the range observed for patients with CrCl 
>50  mL/min. Extensive prespecified comparative analyses for 
the original (MSRIBorig) and revised (MSRIBnew) dose regimens 
in this study provide reassuring data that the labeled dose 
recommendations are safe and effective in patients with renal 
impairment [26].
Receipt of prior and/or concomitant antibiotics did not ap-
pear to confound the assessment of efficacy; subgroup and addi-
tional exploratory analyses evaluating the impact of potentially 
effective prior or concomitant antibiotics demonstrated min-
imal variation in mortality rates across subgroups of patients 
who received the FDA guidance–recommended exposures of 
≤24 hours of prior and/or ≤72 hours of concomitant Gram-
negative antibacterial therapy, including aminoglycosides, vs 
those who received >24 hours of prior and/or >72 hours of con-
comitant Gram-negative therapy [7, 15].
The mortality rates observed in REPROVE were within the 
range reported for other contemporary HAP and VAP clin-
ical trials [4, 27–30]. A  comprehensive review of data from 
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Figure 4. Per-patient favorable microbiological response at TOC (micro-ITT and ME populations). Abbreviations: CAZ-AVI, ceftazidime-avibactam; CAZ-NS, ceftazidime-
nonsusceptible; ME, microbiologically evaluable; micro-ITT, microbiological intent to treat; TOC, test of cure.
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12 (2008–2013) randomized trials in patients with HAP and/
or VAP from the Foundation for the National Institutes of 
Health (FNIH) Biomarkers Consortium reported mortality 
rates from 10% to 30% across studies and HAP/VAP subtypes 
[31], whereas a systematic review of 12 randomized controlled 
trials, including 3571 patients with VAP, reported 28-day all-
cause mortality of 8% to 35% across treatment arms and an 
overall risk of 19% to 20% [30]. The randomized controlled 
trials summarized in the current US treatment guidelines noted 
mortality rates of 8% to 40% across studies and treatment arms 
[4]. Across several of these HAP/VAP studies, mortality rates 
for patients treated with a carbapenem-based regimen, as per 
the comparator arm in the REPROVE study, were frequently 
among the lowest (<15%).
As noted in other studies, the mortality rates observed in 
clinical practice may fall near the higher end of the ranges noted 
above, as inclusion criteria in the controlled clinical trial setting 
generally restrict enrollment to exclude patients with immuno-
suppression, hemodialysis, or other comorbidities. However, 
review of the baseline patient characteristics typically associ-
ated with disease severity (eg, older age, APACHE II scores, re-
sistant pathogens) indicates that the REPROVE study enrolled 
a representative HAP/VAP patient population consistent with 
that of previous trials [7, 31].
In general, reported mortality rates in patients with 
nonventilated HAP are lower than in patients with VAP, and 
the overall mortality rates in REPROVE reflect this. However, 
patients with ventilated HAP have mortality rates approaching 
or exceeding those of patients with VAP, denoting this as a dis-
tinctly high-risk group [31]. Consistent with this observation, 
mortality rates in the REPROVE study were highest in patients 
with ventilated HAP and were balanced across treatment arms 
(CAZ-AVI, 18.8% [9/48]; meropenem, 20.0% [8/40]). Data for 
this subgroup are consistent with the FNIH summary of con-
temporary data [31] and with the primary analysis for the study, 
reinforcing the conclusion of noninferiority between CAZ-AVI 
and meropenem in the current trial.
A potential limitation of this study was that meropenem 
was administered as a 30-minute infusion, consistent with 
the approved product prescribing information [32], whereas 
in clinical practice, there is likely some variation in treat-
ment protocols, in which longer infusions are sometimes 
used for treatment of serious bacterial infections [33–35]. 
Recruitment of patients in the REPROVE study targeted en-
rollment from countries with high rates of HAP/VAP due 
to resistant pathogens. Because the study was originally 
designed to support approval outside the United States, no 
US centers participated in the study. However, patients in the 
study were demographically, clinically, and microbiologically 
representative of a US HAP/VAP population [7, 27, 31].
In summary, analyses of data from the pivotal REPROVE 
study demonstrated the noninferiority of CAZ-AVI to 
meropenem in the treatment of HAP/VAP according to FDA 
guidance–specified end points. CAZ-AVI therefore offers an 
important new treatment option and alternative to carbapenems 
Table 4. Adverse Events Up to Final Patient Follow-up Visit (Safety 
Population)
Summarya
CAZ-AVI  
(n = 436), 
n (%)
Meropenem 
(n = 434),  
n (%)
Any AE 323 (74.1) 321 (74.0)
 Any AE with outcome of deathb 26 (6.0) 23 (5.3)
 Any SAE 79 (18.1) 59 (13.6)
 Any AE leading to discontinuation of 
study drug
16 (3.7) 13 (3.0)
 Any AE of severe intensity 68 (15.6) 55 (12.7)
AEs reported in ≥2% of patients  
in either treatment arm by SOC/ 
preferred term
  
 Infections and infestations   
  Urinary tract infection 11 (2.5) 15 (3.5)
  Pneumonia 10 (2.3) 12 (2.8)
 Blood and lymphatic system 
disorders
  
  Anemia 25 (5.7) 19 (4.4)
 Metabolism and nutrition disorders   
  Hypokalemia 47 (10.8) 37 (8.5)
  Hyponatremia 10 (2.3) 7 (1.6)
 Psychiatric disorders   
  Insomnia 6 (1.4) 11 (2.5)
 Cardiac disorders   
  Cardiac failure 9 (2.1) 6 (1.4)
  Atrial fibrillation 6 (1.4) 9 (2.1)
 Vascular disorders   
  Hypertension 14 (3.2) 17 (3.9)
 Hypotension 10 (2.3) 9 (2.1)
 Respiratory, thoracic, and mediastinal 
disorders
  
  Pleural effusions 10 (2.3) 9 (2.1)
  Respiratory failure 10 (2.3) 6 (1.4)
 Gastrointestinal disorders   
  Diarrhea 67 (15.4) 67 (15.4)
  Constipation 25 (5.7) 32 (7.4)
  Vomiting 25 (5.7) 24 (5.5)
  Nausea 14 (3.2) 7 (1.6)
 Skin and subcutaneous tissue 
disorders
  
  Decubitus ulcer 10 (2.3) 6 (1.4)
  Rash 9 (2.1) 16 (3.7)
 General disorders and administration 
site conditions
  
  Peripheral edema 17 (3.9) 16 (3.7)
  Pyrexia 14 (3.2) 16 (3.7)
 Investigations   
  Increased alanine aminotransferase 17 (3.9) 19 (4.4)
  Increased aspartate 
aminotransferase 
17 (3.9) 17 (3.9)
Abbreviations: AE,  adverse event; CAZ-AVI,  ceftazidime-avibactam; SAE,  serious AE; 
SOC, system organ class.
aPatients with multiple AEs were counted only once for each specific AE category, SOC, 
and/or preferred term.
bDeaths due to disease progression were not included in this category.
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in patients with HAP/VAP caused by Gram-negative pathogens, 
particularly in the setting of proven or suspected bacterial 
resistance.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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